Lipoprotein(a) and the atherosclerotic burden - Should we wait for clinical trial evidence before taking action?
{{output}}
The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer. This review article aims to summarize the latest evidence supporting the causal role of lipoprot... ...
